Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
对于有顺铂禁忌症的局部晚期头颈癌患者，采用西妥昔单抗或度伐利尤单抗联合放疗（NRG-HN004）：一项开放标签、多中心、平行组、随机、II/III期试验
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(24)00507-2
Mell, Loren K; Torres-Saavedra, Pedro A; Wong, Stuart J; Kish, Julie A; Chang, Steven S; Jordan, Richard C; Liu, Tian; Truong, Minh Tam; Winquist, Eric W; Takiar, Vinita; Wise-Draper, Trisha; Robbins, Jared R; Rodriguez, Cristina P; Awan, Musaddiq J; Beadle, Beth M; Henson, Christina; Narayan, Samir; Spencer, Sharon A; Powell, Steven; Dunlap, Neal; Sacco, Assuntina G; Hu, Kenneth Shung; Park, Henry S; Bauman, Julie E; Harris, Jonathan; Yom, Sue S; Le, Quynh-Thu
